FAPI Newsletter Q1 – 2026

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI […]

2026-03-16T20:07:31+00:0013, Mar 2026|Newsletter|

Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence

Magdalena Staniszewska, Ralph Hübner, Camilla Locatelli, Douglas Howard, Matilde Forni, Francis Man, Bent Wilhelm Schoultz, […]

2026-03-13T14:30:00+00:0028, Feb 2026|Publications|

90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis  

Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Pedro Fragoso Costa, Martin Schuler, Sebastian Bauer, […]

2026-03-13T01:32:25+00:0013, Feb 2026|Publications|

Revealing Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma

Emil Novruzov, Eduards Mamlins, Liam Widjaja, Sophie C Siegmund, Tadashi Watabe, Yuriko Mori, Christian Stief, […]

2026-03-13T01:44:24+00:005, Feb 2026|Publications|

Addressing Unmet Needs with [18F]FAPI-74

Presented by: Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE
8th Theranostics World Congress; Cape Town, South […]

2026-02-04T01:17:40+00:004, Feb 2026|Presentations|

SOFIE drives U.S. manufacture of [18F]FAPI-74

Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials […]

2026-01-27T14:57:34+00:0027, Jan 2026|News|

SOFIE’s Phase 2 FAPI Study Outcomes Showcased at ASCO GI 2026

Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological […]

2026-01-23T00:27:04+00:0023, Jan 2026|News|

SOFIE activates FAPI-PRO, second [18F]FAPI-74 Phase 3 trial

FAPI-PRO is a GO!

SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]

2025-12-12T18:06:28+00:0012, Dec 2025|News|
Go to Top